Over 40 managers from Alvogen and Alvotech attended CPhI for the fifth time on the 4th to 6th October. CPhI is the premiere event of the year in the pharma industry calendar and the largest networking event in the world, attracting more than 30,000 visitors from over 140 countries. The show has proven to be a great platform to meet with business colleagues and partners from all over the world and many important business opportunities have been formed at the event.
This year turned out to be yet another success. We’re already looking forward to CPhI 2017 which will be hosted in Frankfurt Germany!
The Alvogen team won three awards this year in the Global Generics and Biosimilars Awards 2016 and over the past three years we have accumulated an impressive record of eight awards, more than any other company in our industry.
The Awards were given for the Regulatory achievement of the year and the Innovation of the year, both for the launch of Reseligo in the CEE region.
The third award was for Business development of the year for the launch of Remurel (glatiramer acetate), the first generic equivalent of Copaxone in Central and Eastern Europe.
These product launches have proven to be a great success in Europe and will help drive strong sales growth this year.